Company intelligence / Profile preview

Microsafe Care

Beverley, South Australia, Australia

Ownership: Private
Development stage: Other

Overview

MicroSafe Care Australia supplies hospital-grade disinfection, dermatology, and wound care products, with flagship product Nanocyn® approved to kill bacteria, SARS-CoV-2 (COVID-19), Norovirus (Gastro), Influenza (H1N1), Fungi, and Mould by up to 99.9999% (6-log reduction) in as little as 15–30 seconds[1][3]. Their solutions are designed for rapid, non-toxic, alcohol-free, and hypoallergenic application across healthcare and industrial settings.

Therapeutic areas: Infectious DiseasesDermatology
Modalities: Small moleculeMedical device
Industry: Consumable Medical Devices

Partnerships

Sonoma Pharmaceuticals

Beyond the preview

Go deeper on Microsafe Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microsafe Care.

Explore the full profile